Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Other Non Operating Income (2016 - 2025)

Collegium Pharmaceutical has reported Other Non Operating Income over the past 5 years, most recently at -$16.0 million for Q4 2025.

  • For Q4 2025, Other Non Operating Income changed N/A year-over-year to -$16.0 million; the TTM value through Dec 2025 reached -$16.0 million, down 41.18%, while the annual FY2025 figure was -$16.0 million, 41.18% down from the prior year.
  • Other Non Operating Income for Q4 2025 was -$16.0 million at Collegium Pharmaceutical, down from -$4.1 million in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $23.5 million in Q1 2023 and troughed at -$47.0 million in Q2 2023.
  • A 3-year average of -$10.2 million and a median of -$7.2 million in 2024 define the central range for Other Non Operating Income.
  • On a YoY basis, Other Non Operating Income climbed as much as 84.72% in 2024 and fell as far as 84.72% in 2024.
  • Year by year, Other Non Operating Income stood at -$47.0 million in 2023, then surged by 91.18% to -$4.1 million in 2024, then crashed by 285.86% to -$16.0 million in 2025.
  • Business Quant data shows Other Non Operating Income for COLL at -$16.0 million in Q4 2025, -$4.1 million in Q3 2024, and -$7.2 million in Q2 2024.